THE UNIVERSITY OF ARIZONA HEALTH NETWORK executed a principles-of-agreement document with Banner Health to create a statewide health care organization and a comprehensive new model for academic medicine. This agreement is intended to lead to final agreements in September.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
